HMGA2 and cancer: Looking at the results of cell viability assay, we find that G4/MTX containing HMGA2 siRNA is a more effective treatment to reduce cell viability than other treatment groups, which maybe a result of the synergistic effect of two therapeutic agents (MTX and HMGA2 specific siRNA) on cancer cells via efficiently exerting cell death in complementary pathways.